Flow cytometry-based results indicated that fisetin treatment induces apoptosis in the cancer cell line via reducing the expression of cyclin-D, c-myc, B cell lymphoma-2, COX-2, MMP-2,-9 and cluster of differentiation (CD) 44 and enhancing the expression of CDK inhibitor 1A/B, E-cadherin and CDKN2D, and caspase-3/9 activity increased through directing the extracellular signal-regulated kinase signaling pathway [103]. This evidence concerns the gene CASP3 and cancer.